HT
BCRX icon

HAP Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History

HAP Trading’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-67,300
Closed -$8K – 1194
2022
Q4 		$8K Buy
67,300
+6,800
+11% +$84.8K ﹤0.01% 1144
2022
Q3 		$31K Buy
60,500
+13,400
+28% +$172K ﹤0.01% 1097
2022
Q2 		$9K Sell
47,100
-20,800
-31% -$215K ﹤0.01% 1491
2022
Q1 		$58K Sell
67,900
-23,700
-26% -$380K ﹤0.01% 1211
2021
Q4 		$98K Buy
91,600
+43,700
+91% +$578K ﹤0.01% 1241
2021
Q3 		$55K Buy
47,900
+3,700
+8% +$58.4K ﹤0.01% 1476
2021
Q2 		$167K Sell
44,200
-37,500
-46% -$510K 0.01% 1066
2021
Q1 		$139K Sell
81,700
-160,400
-66% -$1.65M 0.01% 856
2020
Q4 		$403K Buy
242,100
+218,600
+930% +$1.13M 0.01% 699
2020
Q3 		$13K Sell
23,500
-36,200
-61% -$155K ﹤0.01% 1257
2020
Q2 		$45K Buy
59,700
+13,500
+29% +$53.9K ﹤0.01% 1064
2020
Q1 		$9K Buy
46,200
+19,000
+70% +$52.3K ﹤0.01% 1020
2019
Q4 		$12K Buy
+27,200
New +$68.4K ﹤0.01% 974

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

HAP Trading's BCRX Position: Q4 2022 in Review

HAP Trading sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2022, closing a stake of 17,834 shares — an estimated $222K sold.

HAP Trading first reported a position in BCRX in Q4 2016 and held it in 7 quarters. The position peaked at $1.33M in Q4 2021. 230 funds tracked by Wall St. Rank hold BCRX as of Q4 2022.

  • HAP Trading reported no remaining BioCryst Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • HAP Trading sold 17,834 BioCryst Pharmaceuticals shares in Q4 2022, an estimated $222K.
  • HAP Trading first reported a position in BioCryst Pharmaceuticals in Q4 2016 and held it in 7 quarters.
  • HAP Trading's BioCryst Pharmaceuticals position peaked at $1.33M in Q4 2021.
  • 230 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2022.

Based on HAP Trading's 13F filing for Q4 2022, filed 14 Feb 2023.